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Background
Intrahepatic cholangiocarcinoma (iCCA) is 
an uncommon, aggressive bile duct cancer. 
Two-thirds of iCCA tumors are surgically 
unresectable at diagnosis and prognosis for 
these patients is poor, with median survival 
time of 2.5-7.5 months in absence of 
treatment.1 More than half of unresectable 
iCCA patients die from tumor-related liver 
failure (TRLF), a result of the tumor invading 
and disrupting the nearby parenchyma, 
vasculature, or bile ducts.2
Ablative radiotherapy (ART) has been 
shown to effectively mitigate TRLF and 
improve survival, but fewer than 1 in 6 iCCA 
patients likely to develop TRLF receive this 
treatment.4 This stems from the difficulty of 
prospectively identifying this subgroup of 
patients. To enable automated identification 
of iCCA patients likely to develop TRLF, we 
are developing a model applying the 
predictive ability of deep convolutional 
neural networks (CNNs) to an institutional 
database and pretreatment computed 
tomography (CT) scans for patients with 
unresectable iCCA. We predict that 
intratumoral and peritumoral imaging 
features of iCCA along with clinicopathologic 
features can be used by a CNN to 
accurately predict TRLF.
Conclusions
Our preliminary data indicate a range of 
outcomes for patients and variables that 
may be useful to develop a CNN to predict 
TRLF. Looking forward, we will expand on 
our efforts to annotate patient data as well 
as manually segment CT scans of these 
patients for training of the CNN models. 
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Results
Currently, we have analyzed 175 patients who underwent radiotherapy for 
unresectable iCCA at MD Anderson from 2002-2021. TRLF was found to be the cause 
of death in 13 of 83 patients with a known cause of death.
Methods
We will construct a large institutional database that includes manually segmented CT 
scans, molecular data, and treatment data to train, validate, and test a CNN that can 
accurately predict whether a patient will develop TRLF. To construct an institutional 
database for training of the CNN, we will review records of 700+ patients with iCCA.
Figure 3. Workflow displaying how segmented liver protocol CT images and clinical, pathologic, and molecular data will be 
utilized by a CNN to provide risk of TRLF at 12 months.
Figure 2. Receiver operating characteristic curve of logistic 
prediction model for TRLF using pretreatment clinical 
characteristics. Clinical characteristics alone are inadequate to 
predict TRLF.
Figure 1. iCCA is a malignancy that arises in the periphery of 
the second-order bile ducts.3
Median Range
Age (years) 66 25-89
Tumor Size (cm) 7.3 1.7-18.4
Radiotherapy dose (Gy) 67.5 33-100
Fractions 15 33-100
BED10 (Gy) 98 44-144
Overall Survival (months from diagnosis) 23.9 1.9-163
Overall Survival (months from radiotherapy) 13.7 0.6-153.5
Table 1. Median age, tumor size, radiotherapy treatment conditions, and overall survival.
















Table 2. Percentage of patients by American Joint Committee 
on Cancer 8th Edition Stage at start of radiotherapy. 
Table 3. Overall Survival at one year following radiotherapy.





Table 5. Most common mutations in iCCA patients with 
molecular testing.
Table 4. Percentage of patients by tumor location.
Overall Survival [95% CI] at 1 
year following radiotherapy
All patients 
(n=175)
73% [65-81%]
